keyword
MENU ▼
Read by QxMD icon Read
search

Psilocybin

keyword
https://www.readbyqxmd.com/read/27931907/return-of-the-psychedelics-psilocybin-for-treatment-resistant-depression
#1
Suravi Patra
Psilocybin, the clinically most researched classic psychedelic has recently been tested for its safety and efficacy in a clinical population of treatment resistant depression. The efficacy of psilocybin in clinical depression previously demonstrated in the elecrophysiologic and neuroimaging findings as also in neuropsychological assessments is further validated by the findings of this rigorously conducted randomized trial. Mechanism of action of psilocybin and efficacy in treatment resistant depression are discussed in this paper...
December 2016: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/27909175/psilocybin-promising-results-in-double-blind-trials-require-confirmation-by-real-world-evidence
#2
Alasdair Breckenridge, Diederick E Grobbee
No abstract text is available yet for this article.
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27909174/psilocybin-assisted-psychotherapy-for-dying-cancer-patients-aiding-the-final-trip
#3
David Spiegel
No abstract text is available yet for this article.
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27909173/the-role-of-psychedelics-in-palliative-care-reconsidered-a-case-for-psilocybin
#4
Benjamin Kelmendi, Philip Corlett, Mohini Ranganathan, Cyril D'Souza, John H Krystal
No abstract text is available yet for this article.
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27909171/psilocybin-for-depression-and-anxiety-associated-with-life-threatening-illnesses
#5
John D McCorvy, Reid Hj Olsen, Bryan L Roth
No abstract text is available yet for this article.
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27909170/psilocybin-and-palliative-end-of-life-care
#6
Richard C Shelton, Peter S Hendricks
No abstract text is available yet for this article.
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27909168/psilocybin-in-end-of-life-care-implications-for-further-research
#7
Paul Summergrad
No abstract text is available yet for this article.
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27909167/psilocybin-psychotherapy-or-drug
#8
Guy M Goodwin
No abstract text is available yet for this article.
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27909165/psilocybin-produces-substantial-and-sustained-decreases-in-depression-and-anxiety-in-patients-with-life-threatening-cancer-a-randomized-double-blind-trial
#9
Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedinst
: Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. a high dose (22 or 30 mg/70 kg) of psilocybin administered in counterbalanced sequence with 5 weeks between sessions and a 6-month follow-up...
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27909164/rapid-and-sustained-symptom-reduction-following-psilocybin-treatment-for-anxiety-and-depression-in-patients-with-life-threatening-cancer-a-randomized-controlled-trial
#10
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, Brian L Schmidt
BACKGROUND: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. METHODS: In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were randomly assigned and received treatment with single-dose psilocybin (0...
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27909163/psilocybin-for-anxiety-and-depression-in-cancer-care-lessons-from-the-past-and-prospects-for-the-future
#11
EDITORIAL
David Nutt
No abstract text is available yet for this article.
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27900674/serotonergic-hallucinogen-induced-visual-perceptual-alterations
#12
Michael Kometer, Franz X Vollenweider
Serotonergic hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT), are famous for their capacity to temporally and profoundly alter an individual's visual experiences. These visual alterations show consistent attributes despite large inter- and intra-individual variances. Many reports document a common perception of colors as more saturated, with increased brightness and contrast in the environment ("Visual Intensifications"). Environmental objects might be altered in size ("Visual illusions") or take on a modified and special meaning for the subject ("Altered self-reference")...
November 30, 2016: Current Topics in Behavioral Neurosciences
https://www.readbyqxmd.com/read/27856684/psychedelics-in-the-treatment-of-unipolar-mood-disorders-a-systematic-review
#13
REVIEW
James Jh Rucker, Luke A Jelen, Sarah Flynn, Kyle D Frowde, Allan H Young
Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used extensively in the treatment of mood disorders, and other psychiatric conditions, before their prohibition in the late 1960s...
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27856683/the-challenging-experience-questionnaire-characterization-of-challenging-experiences-with-psilocybin-mushrooms
#14
Frederick S Barrett, Matthew P Bradstreet, Jeannie-Marie S Leoutsakos, Matthew W Johnson, Roland R Griffiths
Acute adverse psychological reactions to classic hallucinogens ("bad trips" or "challenging experiences"), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood), cognitive (confusion, feelings of losing sanity), and somatic (nausea, heart palpitation) symptoms. Responses to items from several hallucinogen-sensitive questionnaires (Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Five-Dimensional Altered States of Consciousness questionnaire) in an Internet survey of challenging experiences with the classic hallucinogen psilocybin were used to construct and validate a Challenging Experience Questionnaire...
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27810345/classical-hallucinogens-and-neuroimaging-a-systematic-review-of-human-studies-hallucinogens-and-neuroimaging
#15
REVIEW
Rafael G Dos Santos, Flávia L Osório, José Alexandre S Crippa, Jaime E C Hallak
Serotonergic hallucinogens produce alterations of perceptions, mood, and cognition, and have anxiolytic, antidepressant, and antiaddictive properties. These drugs act as agonists of frontocortical 5-HT2A receptors, but the neural basis of their effects are not well understood. Thus, we conducted a systematic review of neuroimaging studies analyzing the effects of serotonergic hallucinogens in man. Studies published in the PubMed, Lilacs, and SciELO databases until 12 April 2016 were included using the following keywords: "ayahuasca", "DMT", "psilocybin", "LSD", "mescaline" crossed one by one with the terms "mri", "fmri", "pet", "spect", "imaging" and "neuroimaging"...
December 2016: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/27720453/-new-patterns-of-substance-use-and-abuse-among-french-adolescents-a-knowledge-synthesis
#16
G Jeanne, D Purper-Ouakil, H Rigole, N Franc
AIM: There have been significant changes in adolescent consumption habits over the past fifteen years. New molecules have been synthesized, new devices created and a number of products have increased in popularity; and as a result clinicians sometimes lack information. We chose to focus on this population because of its vulnerability, as adolescents show low sensitivity to long-term outcomes of their actions and may be easily influenced by peers as regards experimentation of new drugs...
October 6, 2016: L'Encéphale
https://www.readbyqxmd.com/read/27714429/alterations-of-consciousness-and-mystical-type-experiences-after-acute-lsd-in-humans
#17
Matthias E Liechti, Patrick C Dolder, Yasmin Schmid
RATIONALE: Lysergic acid diethylamide (LSD) is used recreationally and in clinical research. Acute mystical-type experiences that are acutely induced by hallucinogens are thought to contribute to their potential therapeutic effects. However, no data have been reported on LSD-induced mystical experiences and their relationship to alterations of consciousness. Additionally, LSD dose- and concentration-response functions with regard to alterations of consciousness are lacking. METHODS: We conducted two placebo-controlled, double-blind, cross-over studies using oral administration of 100 and 200 μg LSD in 24 and 16 subjects, respectively...
October 7, 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27684102/psilocybin-for-treating-substance-use-disorders
#18
Bas T H de Veen, Arnt F A Schellekens, Michel M M Verheij, Judith R Homberg
INTRODUCTION: Evidence based treatment for Substance use disorders (SUD) includes psychotherapy and pharmacotherapy. However, these are only partially effective. Hallucinogens, such as psilocybin, may represent potential new treatment options for SUD. This review provides a summary of (human) studies on the putative therapeutic effects of psilocybin, and discusses the receptor systems, brain regions and cognitive and emotional processes mediating psilocybin's effects. Psilocybin's chemical structure is similar to that of serotonin...
August 12, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27578767/survey-study-of-challenging-experiences-after-ingesting-psilocybin-mushrooms-acute-and-enduring-positive-and-negative-consequences
#19
Theresa M Carbonaro, Matthew P Bradstreet, Frederick S Barrett, Katherine A MacLean, Robert Jesse, Matthew W Johnson, Roland R Griffiths
Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst "bad trip") after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging experiences of his/her lifetime. Eleven percent put self or others at risk of physical harm; factors increasing the likelihood of risk included estimated dose, duration and difficulty of the experience, and absence of physical comfort and social support...
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27558746/it-s-time-to-take-psilocybin-seriously-as-a-possible-treatment-for-substance-use-disorders
#20
Michael P Bogenschutz
No abstract text is available yet for this article.
August 24, 2016: American Journal of Drug and Alcohol Abuse
keyword
keyword
20841
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"